



# COVID-19

## Questions, Answers and Actions

### *Vitamin D and infection risk*

**Question:** "What is the evidence that vitamin D status affects the risk of infection with COVID-19?"

**Answer:** The Scientific Advisory Committee on Nutrition (SACN) [2016 report on vitamin D and health](#) found that "Evidence on vitamin D and infection is inconsistent and mainly observational. RCTs do not generally show a beneficial effect of vitamin D supplementation on infectious disease risk."<sup>1</sup>

There is some evidence from observational and randomised trials that serum 25-hydroxy-vitamin D (25(OH)D) levels may alter the risk of acute respiratory tract infections (RTIs), but meta-analyses examining the role of vitamin D supplementation in RTI have varying results. To quote the SACN:

"Out of 3 systematic reviews/meta-analyses of RCTs on the effect of vitamin D supplementation on RTIs, 1 reported beneficial effects of vitamin D supplementation in reducing RTI risk, 1 reported no effect, and 1 reported conflicting results. The majority of RCTs published since the meta-analyses also did not find that vitamin D supplementation reduced RTI risk. Findings from cohort studies are generally supportive of an inverse association between serum 25(OH)D concentration and RTIs, with serum 25(OH)D concentrations ranging between < 25 and <50 nmol/L associated with increased risk for developing RTIs". It should be noted that observational studies, including cohort studies, cannot prove causation and are subject to confounding.

**In the winter months, at up to 40% of the UK population may be considered deficient in 25(OH)D (serum levels <25 nmol/L), and a much larger proportion are likely to have levels considered insufficient (<50 nmol/L).**<sup>1</sup> Average annualised serum 25(OH)D levels vary with ethnicity, and do not reach the threshold for sufficiency in any ethnic group: 45.8 nmol/L in white adults, 20.5 nmol/L in Asian adults, and 27.7 nmol/L in black adults. Annualised levels in institutionalised adults were 30 nmol/L.<sup>1</sup>

Vitamin D testing will not affect clinical management for the majority of patients and therefore has a limited place in clinical practice. Testing should be reserved for scenarios where the result will influence clinical management (e.g. osteomalacia/rickets) or prior to a specific treatment (e.g. antiresorptive treatments such as IV bisphosphonates). Testing is not indicated as part of the management or prophylaxis of COVID-19, and there is no direct evidence that vitamin D status affects the risk of COVID-19 infection specifically.

#### **Action:**

- Reinforce usual advice around vitamin D supplementation. Adults and children over 5 should consider taking a daily supplement containing 10 micrograms (400 units) of vitamin D.<sup>1,2</sup> Suitable products for supplementation can be bought OTC and should not be prescribed; see NHSE guidance on [Conditions for which OTC items should not routinely be prescribed in primary care](#).<sup>3</sup>
- If deficiency is suspected then consideration may be given to administering a treatment dose, but this must be prescribed; there are no suitable licensed products available OTC. Guidance on dosing regimens is available from [NICE CKS](#).<sup>4</sup>
- Vitamin D can be produced in the skin in response to exposure to sunlight in the UK between April and September.<sup>1,2</sup> Adults and children may consider daily safe sun exposure, but must adhere to [government advice on leaving the home safely](#).<sup>5</sup>

## References

1. Scientific Advisory Committee on Nutrition. Vitamin D and Health. 2016. Accessed via [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/537616/SACN\\_Vitamin\\_D\\_and\\_Health\\_report.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/537616/SACN_Vitamin_D_and_Health_report.pdf) on 07/04/20.
2. NHS.uk. Vitamin D. Accessed via <https://www.nhs.uk/conditions/vitamins-and-minerals/vitamin-d/> on 07/04/20
3. NHS England. Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs. March 2018, available from <https://www.england.nhs.uk/wp-content/uploads/2018/03/otc-guidance-for-ccgs.pdf>
4. NICE Clinical Knowledge Summaries. Vitamin D deficiency in adults - treatment and prevention. Last revised September 2018. Accessed via <https://cks.nice.org.uk/vitamin-d-deficiency-in-adults-treatment-and-prevention#!scenario> on 07/04/20
5. Cabinet Office. Coronavirus outbreak FAQs: what you can and can't do. Published 29 March 2020. Accessed via <https://www.gov.uk/government/publications/coronavirus-outbreak-faqs-what-you-can-and-cant-do/coronavirus-outbreak-faqs-what-you-can-and-cant-do> on 07/04/20



NHS

**Version:** 1.0

**Date prepared:** 9<sup>th</sup> April 2020

**Prepared by:** Nancy Kane. Regional Drug and Therapeutics Centre.

**Review date:** Ongoing

**Regional Drug and Therapeutics Centre  
16/17 Framlington Place, Newcastle upon Tyne, NE2 4AB**

Tel: 0191 213 7855 Fax: 0191 261 8839  
E-mail: [nuth.nyrdtc.rxsupp@nhs.net](mailto:nuth.nyrdtc.rxsupp@nhs.net) Website: [www.rdtc.nhs.uk](http://www.rdtc.nhs.uk)

